Altimmune, Inc. (3G0.F)
| Previous close | 8.20 |
| Open | 8.10 |
| Bid | 7.36 x 440000 |
| Ask | 7.40 x 420000 |
| Day's range | 8.10 - 8.10 |
| 52-week range | 1.97 - 13.70 |
| Volume | |
| Avg. volume | 640 |
| Market cap | 574.095M |
| Beta (5Y monthly) | 0.20 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.47 |
| Earnings date | 08 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 20 Jan 2017 |
| 1y target est | 30.86 |
Simply Wall St.Altimmune First Quarter 2024 Earnings: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023)
Altimmune ( NASDAQ:ALT ) First Quarter 2024 Results Key Financial Results Net loss: US$24.4m (loss widened by 22% from...
GlobeNewswireAltimmune Announces First Quarter 2024 Financial Results and Provides a Business Update
Enrollment ongoing in IMPACT Phase 2b trial of pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH), with top line results expected in Q1 2025 Cash, cash equivalents and short-term investments of $182.1 million at March 31, 2024 Webcast to be held today, May 9, 2024, at 8:30 am ET GAITHERSBURG, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the first quarter ended March 31, 2
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The s
